Acutaas Chemicals Q3 FY26 Revenue Soars 43% to ₹393 Crore, PAT Jumps 133%
Acutaas Chemicals reported a 43% YoY revenue increase to ₹393.2 crore for Q3 FY26. PAT surged 133.7% to ₹106.2 crore. The company revised its revenue growth guidance to ~30% based on strong CDMO ramp-up and specialty chemicals growth. New verticals like battery and semiconductor chemicals are progressing.
The substantial financial growth, strategic expansion into new verticals, and upward revision of guidance are material events that are likely to significantly impact investor perception and the company's valuation.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with an upward revision of its revenue growth guidance, indicating strong financial performance and positive future outlook.
Acutaas Chemicals Limited (formerly Ami Organics Limited) has released its investor presentation for the third quarter and nine months ended December 31, 2025. The company reported a significant 43.0% year-on-year increase in revenue from operations for Q3 FY26, reaching ₹3,932 million (₹393.2 crore). EBITDA for the quarter surged by 119.4% to ₹1,507 million (₹150.7 crore), with PAT (Profit After Tax) rising by an impressive 133.7% to ₹1,062 million (₹106.2 crore).
For the nine-month period ended December 31, 2025 (9MFY26), revenue from operations grew by 29.8% to ₹9,066 million (₹906.6 crore), and PAT increased by 127.3% to ₹2,221 million (₹222.1 crore). The company highlighted robust growth in its Advanced Pharmaceutical Intermediates business, supported by a strong ramp-up in its CDMO (Contract Development and Manufacturing Organization) operations, while its specialty chemicals business also demonstrated steady growth.
Management commentary indicates a strategic focus on reinforcing the core pharmaceutical intermediates business and expanding CDMO opportunities. The company is also strengthening its foundation by scaling battery chemicals and semiconductor chemicals verticals, which are under active capital investment and expected to become self-sustaining growth engines within three years. Due to a healthy order book and improved visibility, Acutaas Chemicals has revised its revenue growth guidance upward from 25% to approximately 30% for the fiscal year.
The presentation also detailed financial performance over the years, showing consistent revenue growth and improving profitability. The balance sheet indicates substantial growth in non-current assets, particularly property, plant, and equipment, and capital work-in-progress, reflecting ongoing investments. Shareholding information as of December 31, 2025, shows a market capitalization of ₹13,958 crore.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.